Table 3.
Mean LY2510924 Pharmacokinetic Parameters Following a 20-, 30-, or 40-mg Dose
| Geometric mean (CV%) | |||
|---|---|---|---|
| LY2510924 dose (mg/day) | 20 (n = 3) | 30 (n = 3) | 40 (n = 3) |
| Day 1 | |||
| Cmax (ng/mL) | 746.68 (56) | 682.34 (19) | 1857.93 (53) |
| Day 15 | |||
| Cmax (ng/mL) | 366.67 (169) | 847.27 (15) | 1678.77 (54) |
| AUC (0–inf) (ng × h/mL) | 1960 (258) | 4320 (11) | 6210-170000a |
| CL/F (L/h) | 10.8 (243) | 7.37 (10) | 4.10 (52) |
| t1/2b (h) | 5.11 (3.11–7.53) | 5.98 (5.43–7.15) | 7.01–9.14a |
| Vd/F (L) | 79.5 (137) | 63.6 (16) | 36.1–71.2a |
a
n = 2, individual values reported.
b
Geometric mean (range).
%CV, coefficient of variation; AUC(0–inf), area under the plasma concentration time curve from time zero to infinity; CL/F, apparent clearance; Cmax, maximum plasma concentration; N, number of patients who received dose; t1/2:elimination half-life; Vd/F, apparent volume of distribution.